Sign in or create an account to add this stock to your watchlist.
About MacroGenics (NASDAQ:MGNX)
MacroGenics, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States. The company's advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers. It is also developing Flotetuzumab, a DART molecule that targets CD123 and CD3; MGA012, a monoclonal antibody, which targets programmed cell death protein 1 (PD-1); MGD013, a DART molecule that enables the co-blockade with a single recombinant agent of two immune checkpoint molecules; MGD019, a preclinical DART molecule designed to recognize the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and Enoblituzumab, a monoclonal antibody that targets B7-H3. In addition, the company develops MGD009, a DART molecule recognizes B7-H3 and CD3; MGC018, a B7-H3 antibody-drug conjugate; MGD007, a DART molecule, which targets glycoprotein A33 and CD3; Teplizumab, an anti-CD3 monoclonal antibody to treat type 1 diabetes; MGD010, a DART molecule designed to address limitations of existing B cell-targeted therapies by binding to the CD32B and CD79B proteins found on human B cells; and MGD014, a DART molecule that targets the envelope protein of human immunodeficiency virus, or HIV-infected cells and CD3-expressing T cells. It has strategic collaborations with Incyte Corporation; Les Laboratoires Servier and Institut de Recherches Servier; and F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MGNX
CUSIPN/A
Phone301-251-5172
Debt
Debt-to-Equity RatioN/A
Current Ratio5.43
Quick Ratio5.43
Price-To-Earnings
Trailing P/E Ratio-40.20
Forward P/E Ratio-4.54
P/E GrowthN/A
Sales & Book Value
Annual Sales$157.74 million
Price / Sales5.81
Cash FlowN/A
Price / CashN/A
Book Value$8.13 per share
Price / Book2.67
Profitability
EPS (Most Recent Fiscal Year)($0.54)
Net Income$-19,620,000.00
Net Margins-19.64%
Return on Equity-13.03%
Return on Assets-10.36%
Miscellaneous
Employees330
Outstanding Shares42,200,000
MacroGenics (NASDAQ:MGNX) Frequently Asked Questions
What is MacroGenics' stock symbol?
MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."
How were MacroGenics' earnings last quarter?
MacroGenics (NASDAQ:MGNX) posted its earnings results on Tuesday, February, 27th. The biopharmaceutical company reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.58 by $0.22. The biopharmaceutical company earned $152.36 million during the quarter, compared to analysts' expectations of $152.59 million. MacroGenics had a negative return on equity of 13.03% and a negative net margin of 19.64%. View MacroGenics' Earnings History.
What price target have analysts set for MGNX?
10 Wall Street analysts have issued twelve-month price objectives for MacroGenics' shares. Their predictions range from $22.00 to $44.00. On average, they anticipate MacroGenics' share price to reach $31.2857 in the next year. View Analyst Ratings for MacroGenics.
Are investors shorting MacroGenics?
MacroGenics saw a decline in short interest in April. As of April 13th, there was short interest totalling 3,055,741 shares, a decline of 24.3% from the March 30th total of 4,034,237 shares. Based on an average daily trading volume, of 405,524 shares, the days-to-cover ratio is presently 7.5 days. Approximately 9.4% of the shares of the stock are sold short.
Who are some of MacroGenics' key competitors?
Some companies that are related to MacroGenics include Blueprint Medicines (BPMC), Array Biopharma (ARRY), Ultragenyx Pharmaceutical (RARE), Amicus Therapeutics (FOLD), Supernus Pharmaceuticals (SUPN), Ascendis Pharma (ASND), Ironwood Pharmaceuticals (IRWD), Portola Pharmaceuticals (PTLA), Clovis Oncology (CLVS), Tesaro (TSRO), Emergent BioSolutions (EBS), Horizon Pharma (HZNP), Global Blood Therapeutics (GBT), The Medicines (MDCO) and Heron Therapeutics (HRTX).
Who are MacroGenics' key executives?
MacroGenics' management team includes the folowing people:
- Dr. Scott Koenig, CEO, Pres & Director (Age 66)
- Mr. James Karrels, Sr. VP, CFO & Sec. (Age 51)
- Dr. Ezio Bonvini, Sr. VP of Research & Chief Scientific Officer (Age 64)
- Mr. Eric Blasius Risser, Sr. VP of Bus. Devel. & Portfolio Management and Chief Bus. Officer (Age 45)
- Dr. Jon M. Wigginton, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 56)
Has MacroGenics been receiving favorable news coverage?
News stories about MGNX stock have trended somewhat positive this week, Accern reports. The research firm rates the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. MacroGenics earned a media sentiment score of 0.19 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 46.99 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are MacroGenics' major shareholders?
MacroGenics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include OppenheimerFunds Inc. (9.36%), BlackRock Inc. (6.32%), Wasatch Advisors Inc. (2.42%), Millennium Management LLC (2.13%), Pinnacle Associates Ltd. (1.87%) and Hood River Capital Management LLC (1.54%). Company insiders that own MacroGenics stock include Eric Blasius Risser, James Karrels, Jon Marc Wigginton and Lynn Cilinski. View Institutional Ownership Trends for MacroGenics.
Which institutional investors are selling MacroGenics stock?
MGNX stock was sold by a variety of institutional investors in the last quarter, including DekaBank Deutsche Girozentrale, Prosight Management LP, DAFNA Capital Management LLC, Pinnacle Associates Ltd., Wasatch Advisors Inc., Sphera Funds Management LTD. and Legal & General Group Plc. Company insiders that have sold MacroGenics company stock in the last year include Eric Blasius Risser, James Karrels, Jon Marc Wigginton and Lynn Cilinski. View Insider Buying and Selling for MacroGenics.
Which institutional investors are buying MacroGenics stock?
MGNX stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Victory Capital Management Inc., CVI Holdings LLC, Spark Investment Management LLC, Rock Springs Capital Management LP, Landscape Capital Management L.L.C., Citadel Advisors LLC and Trexquant Investment LP. View Insider Buying and Selling for MacroGenics.
How do I buy shares of MacroGenics?
Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MacroGenics' stock price today?
One share of MGNX stock can currently be purchased for approximately $21.72.
How big of a company is MacroGenics?
MacroGenics has a market capitalization of $917.90 million and generates $157.74 million in revenue each year. The biopharmaceutical company earns $-19,620,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. MacroGenics employs 330 workers across the globe.
How can I contact MacroGenics?
MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at 301-251-5172.
MarketBeat Community Rating for MacroGenics (MGNX)
MarketBeat's community ratings are surveys of what our community members think about MacroGenics and other stocks. Vote "Outperform" if you believe MGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
MacroGenics (NASDAQ:MGNX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
10 Wall Street analysts have issued ratings and price targets for MacroGenics in the last 12 months. Their average twelve-month price target is $31.2857, suggesting that the stock has a possible upside of 44.04%. The high price target for MGNX is $44.00 and the low price target for MGNX is $22.00. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.80 | 2.80 | 2.82 | 2.82 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $31.2857 | $31.8571 | $31.8889 | $31.3333 |
| Price Target Upside: | 44.04% upside | 41.09% upside | 37.27% upside | 71.69% upside |
MacroGenics (NASDAQ:MGNX) Consensus Price Target History
MacroGenics (NASDAQ:MGNX) Analyst Ratings History
Show:
(Data available from 5/22/2016 forward)
MacroGenics (NASDAQ:MGNX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
MacroGenics (NASDAQ MGNX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 8.82%
Institutional Ownership Percentage: 89.25%
MacroGenics (NASDAQ MGNX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/12/2018 | Eric Blasius Risser | SVP | Sell | 1,000 | $31.08 | $31,080.00 | 10,100 |  |
| 3/5/2018 | James Karrels | CFO | Sell | 5,000 | $31.00 | $155,000.00 | | |
| 3/2/2018 | Eric Blasius Risser | SVP | Sell | 4,000 | $30.00 | $120,000.00 | 13,100 | |
| 2/28/2018 | Eric Blasius Risser | SVP | Sell | 1,000 | $25.01 | $25,010.00 | | |
| 2/28/2018 | Lynn Cilinski | VP | Sell | 23,967 | $25.01 | $599,414.67 | | |
| 1/24/2018 | Eric Blasius Risser | SVP | Sell | 3,000 | $22.50 | $67,500.00 | 12,100 | |
| 1/17/2018 | Jon Marc Wigginton | SVP | Sell | 5,000 | $20.00 | $100,000.00 | | |
| 11/21/2017 | Jon Marc Wigginton | SVP | Sell | 5,000 | $20.00 | $100,000.00 | 35,000 | |
| 10/25/2017 | Jon Marc Wigginton | SVP | Sell | 10,000 | $20.00 | $200,000.00 | 40,000 | |
| 6/5/2017 | Jon Marc Wigginton | SVP | Sell | 5,000 | $20.00 | $100,000.00 | 35,000 | |
| 4/19/2017 | Jon Marc Wigginton | SVP | Sell | 15,000 | $20.00 | $300,000.00 | 45,000 | |
| 10/3/2016 | Jon Marc Wigginton | CMO | Sell | 10,000 | $29.34 | $293,400.00 | 10,000 | |
| 10/3/2016 | Lynn Cilinski | VP | Sell | 6,231 | $29.28 | $182,443.68 | 8,154 | |
| 8/1/2016 | Jon Marc Wigginton | SVP | Sell | 20,000 | $30.78 | $615,600.00 | 20,000 | |
| 7/1/2016 | Jon Marc Wigginton | CMO | Sell | 5,000 | $27.22 | $136,100.00 | 5,000 | |
| 7/1/2016 | Lynn Cilinski | VP | Sell | 8,922 | $27.22 | $242,856.84 | 10,845 | |
| 5/27/2016 | Lynn Cilinski | VP | Sell | 5,000 | $25.00 | $125,000.00 | 6,923 | |
| 3/3/2016 | Paulo F Costa | Director | Buy | 10,000 | $17.20 | $172,000.00 | 59,435 | |
| 1/4/2016 | Jon Marc Wigginton | SVP | Sell | 10,000 | $29.64 | $296,400.00 | | |
| 11/23/2015 | Lynn Cilinski | VP | Sell | 6,921 | $35.00 | $242,235.00 | 1,923 | |
| 11/16/2015 | Ezio Bonvini | VP | Sell | 3,117 | $31.44 | $97,998.48 | 70,317 | |
| 10/15/2015 | Ezio Bonvini | VP | Sell | 6,233 | $25.21 | $157,133.93 | 73,434 | |
| 10/1/2015 | Jon Marc Wigginton | SVP | Sell | 5,000 | $21.11 | $105,550.00 | | |
| 7/10/2015 | Ezio Bonvini | VP | Sell | 2,400 | $38.09 | $91,416.00 | | |
| 7/1/2015 | Jon Marc Wigginton | SVP | Sell | 5,000 | $37.15 | $185,750.00 | | |
| 7/1/2015 | Lynn Cilinski | VP | Sell | 6,921 | $37.15 | $257,115.15 | | |
| 6/30/2015 | Ezio Bonvini | VP | Sell | 6,497 | $38.07 | $247,340.79 | | |
| 6/24/2015 | Ezio Bonvini | VP | Sell | 6,097 | $38.08 | $232,173.76 | | |
| 6/23/2015 | Ezio Bonvini | VP | Sell | 13,054 | $38.14 | $497,879.56 | | |
| 6/15/2015 | Ezio Bonvini | VP | Sell | 6,233 | $34.01 | $211,984.33 | | |
| 5/15/2015 | Ezio Bonvini | VP | Sell | 6,233 | $30.24 | $188,485.92 | | |
| 4/15/2015 | Ezio Bonvini | VP | Sell | 6,233 | $33.98 | $211,797.34 | | |
| 2/2/2015 | Jon Marc Wigginton | SVP | Sell | 5,000 | $31.04 | $155,200.00 | | |
| 12/22/2014 | Kathryn E Stein | SVP | Sell | 10,946 | $37.00 | $405,002.00 | | |
| 12/18/2014 | Eric Blasius Risser | VP | Sell | 10,000 | $33.50 | $335,000.00 | | |
| 12/18/2014 | Kathryn E Stein | SVP | Sell | 10,946 | $33.00 | $361,218.00 | | |
| 11/24/2014 | Eric Blasius Risser | VP | Sell | 10,000 | $27.75 | $277,500.00 | | |
| 11/21/2014 | Kathryn E Stein | VP | Sell | 10,946 | $27.00 | $295,542.00 | | |
| 11/17/2014 | Kathryn E Stein | VP | Sell | 25,301 | $23.30 | $589,513.30 | | |
| 11/13/2014 | Eric Blasius Risser | VP | Sell | 25,000 | $23.80 | $595,000.00 | | |
| 10/1/2014 | Jon Marc Wigginton | VP | Sell | 5,000 | $20.48 | $102,400.00 | | |
| 9/2/2014 | Eric Blasius Risser | VP | Sell | 8,316 | $20.89 | $173,721.24 | | |
| 8/18/2014 | Jon Marc Wigginton | VP | Sell | 5,000 | $20.52 | $102,600.00 | | |
| 6/30/2014 | Eric Blasius Risser | VP | Sell | 8,000 | $21.84 | $174,720.00 | | |
| 5/29/2014 | Kathryn E Stein | VP | Sell | 10,946 | $19.75 | $216,183.50 | | |
| 2/18/2014 | Edward Hurwitz | Director | Sell | 308,513 | $36.50 | $11,260,724.50 | | |
| 10/16/2013 | Kenneth Galbraith | Director | Buy | 46,875 | $16.00 | $750,000.00 | | |
(Data available from 1/1/2013 forward)
MacroGenics (NASDAQ MGNX) News Headlines
| Source: |
|
MacroGenics (NASDAQ:MGNX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
MacroGenics (NASDAQ:MGNX) Income Statement, Balance Sheet and Cash Flow Statement
MacroGenics (NASDAQ MGNX) Stock Chart for Tuesday, May, 22, 2018
Loading chart…
